|View printer-friendly version|
This financing consists of a
"In today's volatile financial markets, the ability to secure this type of capital financing with Cerberus and eliminate the potential issuance of approximately 10.6 million shares of our common stock demonstrates our progress in commercial execution and shows confidence in our long-term financial plans and stability," said
Further information on
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Established in 1992,
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-closes-70-million-straight-debt-financing-300202733.html
Investors: Chris Dailey, Investor Relations, EVC Group, +1 (646) 445-4801, Cdailey@evcgroup.com, Media: Beth Kaplan, Public Relations Director, Accuray, +1 (408) 789-4426, firstname.lastname@example.org
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.